However, response rates to CTX130 were low in a phase 1 solid tumor RCC study, though one of 16 patients achieved a complete response, thereby demonstrating the promise of CD70-targeted T-cell therapies for RCC (45). This evidence concerns the gene CD70 and renal cell carcinoma.